Substantial weight losstypically 5-10% or more of baseline body weightproduces measurable improvements in cardiovascular risk factors , including blood pressure, lipid profiles, inflammatory markers, and glycemic control
Week 6 through week 8 tends to be the most intense window
GLP-1 products have the potential to narrow health disparities by addressing a key driver of chronic disease
Testing helps your clinician determine whether you'll benefit most from semaglutide alone or dual-compound GLP-Squared, avoiding unnecessary medication switches
LiangDFengYZandkarimiFWangHZhangZKimJet alFerroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
MEDICATION TRACKING Log every dose of Ozempic, Wegovy, Mounjaro, Saxenda, Rybelsus, and other GLP-1 medications